A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial
To assess the long-term safety and tolerability of oral OPC-34712 (brexpiprazole), given in addition to an FDA approved antidepressant (ADT) for the treatment of adults with Major Depressive Disorder (MDD)
Inclusion Criteria:
Eligible subjects from Trials 331-10-227, 331-10-228 or 331-12-282:
Eligible subjects from other Phase 3, Double-blind, Brexpiprazole MDD trials:
• Subjects who completed the last scheduled visit of the prior Double-blind Randomized Phase 3 trial.
Exclusion Criteria:
Tom River, New Jersey, United States
Arkhangelsk Region, Russia
Saint Petersberg, Russia